PROM1 and melanoma: Our investigations have shown that silencing CD133 in FEMX-I cells, an aggressive melanoma cell line derived from a lymph node metastasis of a patient with malignant melanoma [12, 13], negatively affected their growth and motility as well as their potential to metastasize upon injection in a murine model [14].